$115 million supports development of bioprinted cell therapies
Bioprinted tissue therapeutics company Aspect Biosystems has closed a $115 million Series B financing round. The financing was led by Dimension, and included Novo Nordisk, Radical Ventures, an undisclosed leading global investment firm, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund: A Breakthrough T1D Venture. Read More